TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tissue Regenix ( (GB:TRX) ) has shared an update.
Tissue Regenix has announced significant changes to its Board of Directors, with Jay LeCoque appointed as the new Executive Chairman. LeCoque brings over 25 years of experience in senior management within the life sciences sector, which is expected to strengthen the company’s growth and earnings. The resignations of Jonathan Glenn and Trevor Phillips from the Board were also announced, with the company expressing gratitude for their contributions. The appointment of LeCoque is seen as a strategic move to enhance the company’s position in the global healthcare and clinical life sciences market.
The most recent analyst rating on (GB:TRX) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on Tissue Regenix stock, see the GB:TRX Stock Forecast page.
Spark’s Take on GB:TRX Stock
According to Spark, TipRanks’ AI Analyst, GB:TRX is a Neutral.
The overall stock score is primarily influenced by the company’s financial performance, which shows some operational improvements but remains challenged by net losses and negative cash flows. Technical analysis indicates a bearish trend, and valuation concerns are highlighted by a negative P/E ratio and lack of dividend yield. These factors collectively suggest caution for potential investors.
To see Spark’s full report on GB:TRX stock, click here.
More about Tissue Regenix
Tissue Regenix is a leading medical device company in regenerative medicine, specializing in decellularisation technology (dCELL®) that removes DNA and other cellular material from animal and human soft tissue. This technology creates an acellular tissue scaffold that is not rejected by the patient’s body, and is used for repairing damaged body structures, with applications in sports medicine, foot and ankle injuries, and wound care.
Average Trading Volume: 72,214
Technical Sentiment Signal: Sell
Current Market Cap: £21.37M
Find detailed analytics on TRX stock on TipRanks’ Stock Analysis page.